Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy
Lung Cancer
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Lung Neoplasms
Conditions: Keywords
recurrent non-small cell lung cancer, stage IIIB non-small cell lung cancer, stage IV non-small cell lung cancer
Study Type
Study Phase
Phase 2
Study Design
Masking: Open Label, Primary Purpose: Treatment
Name: erlotinib hydrochloride Type: Drug
Name: sorafenib tosylate Type: Drug
Name: DNA analysis Type: Genetic
Name: mutation analysis Type: Genetic
Name: polymerase chain reaction Type: Genetic
Name: protein analysis Type: Genetic
Name: protein expression analysis Type: Genetic
Name: immunohistochemistry staining method Type: Other
Name: laboratory biomarker analysis Type: Other
Overall Status
RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Giving sorafenib together with erlotinib may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving sorafenib together with erlotinib works in treating patients with stage IIIB or stage IV non-small cell lung cancer that has not responded to chemotherapy.
Detailed Description


- To assess the response rate of sorafenib tosylate in combination with erlotinib hydrochloride in patients with stage IIIB-IV non-small cell lung cancer refractory to 1 or 2 prior chemotherapy regimens.


- To assess the response duration in patients treated with this regimen.

- To assess the disease control rate in patients treated with this regimen.

- To assess the progression-free survival of patients treated with this regimen.

- To assess the overall survival of patients treated with this regimen.

- To assess the safety and tolerability of this regimen in these patients.

- To analyze biomarkers, including evaluation of EGFR expression, mutational analysis of EGFR and K-ras, and immunohistochemical analysis of EGFR downstream pathway (phospho-EGFR, phospho-AKT, phospho-Erk, phospho-STAT3).

OUTLINE: This is a multicenter study.

Patients receive oral erlotinib hydrochloride once daily and oral sorafenib tosylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Tissue samples are analyzed at the nucleic acid level for EGFR mutation (exon 18-21) and K-ras mutation (exon 2), DNA mutations via PCR, presence of EGFR protein by IHC, and downstream effectors of EGFR activation by IHC.

After completion of study therapy, patients are followed periodically.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both

- Histologically or cytologically confirmed non-small cell lung cancer

- Advanced (stage IIIB-IV) or recurrent disease

- Must have failed 1 or 2 prior chemotherapy regimens, including platinum-containing regimen

- At least 1 unidimensionally measurable lesion > 10 mm by spiral CT scan or > 20 mm by conventional CT scan

- Previously irradiated lesions cannot be included as sites of measurable disease unless clear tumor progression has been documented in the lesions since the end of radiotherapy

- No known or suspected brain metastases

- Patients with clinical signs or symptoms that are suspicious of brain metastasis must have a pre-treatment CT scan or MRI of the brain

- Patients with prior brain metastases are eligible provided they have completed their treatment for brain metastases, no longer require corticosteroids, and are asymptomatic


- ECOG performance status 0-2

- WBC 4,000-12,000/μL

- Neutrophil ≥ 1,500/μL

- Platelet count ≥ 100,000/μL

- Hemoglobin ≥ 9.0 g/dL

- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

- AST and ALT ≤ 2.0 times ULN

- Alkaline phosphatase ≤ 2.0 times ULN

- Serum creatinine ≤ 1.5 times ULN

- Not pregnant or nursing

- No active clinically serious infections

- No prior or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1), or any cancer curatively treated > 5 years before study

- Able to swallow oral medications

- No substance abuse or medical, psychological, or social conditions that may interfere with participation in the study or evaluation of the study results


- See Disease Characteristics

- Recovered from all prior therapy

- No prior anti-EGFR targeted therapy

- At least 4 weeks since prior surgery

- At least 4 weeks since prior and no concurrent radiotherapy

- No prior radiotherapy to the whole pelvis or chest or to ≥ 25% of the bone marrow

- No other concurrent anticancer agents (e.g., chemotherapy or immunotherapy agents) which might affect evaluation of study treatment
Yonsei Cancer Center at Yonsei University Medical Center
Seoul, Korea, Republic of
Status: Recruiting
Contact: Joo-Hang Kim, MD - 82-2-2228-8131 -
Start Date
September 2008
Yonsei University
National Cancer Institute (NCI)
Record processing date processed this data on July 28, 2015 page